Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) from a neutral rating to an overweight rating in a research note released on Thursday, MarketBeat Ratings reports. Cantor Fitzgerald currently has $167.00 price target on the biotechnology company's stock, up from their prior price target of $152.00.

A number of other equities analysts have also recently weighed in on SRPT. Raymond James reissued an "outperform" rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Citigroup dropped their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. UBS Group raised their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. Finally, Needham & Company LLC reissued a "buy" rating and set a $205.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 14th. One research analyst has rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $181.33.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $7.55 during midday trading on Thursday, hitting $120.42. The company's stock had a trading volume of 2,392,656 shares, compared to its average volume of 776,954. Sarepta Therapeutics has a 12 month low of $75.85 and a 12 month high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $11.48 billion, a PE ratio of 267.61 and a beta of 0.81. The stock's 50-day moving average price is $126.54 and its 200-day moving average price is $132.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business's revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.27) EPS. Analysts anticipate that Sarepta Therapeutics will post 1.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the company's stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company's stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Fifth Third Wealth Advisors LLC acquired a new stake in Sarepta Therapeutics during the second quarter worth $607,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at about $4,771,000. Securian Asset Management Inc. bought a new stake in Sarepta Therapeutics in the second quarter valued at about $1,187,000. Natixis Advisors LLC acquired a new position in Sarepta Therapeutics in the second quarter worth about $1,918,000. Finally, Oppenheimer Asset Management Inc. raised its position in Sarepta Therapeutics by 32.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 3,604 shares of the biotechnology company's stock worth $467,000 after purchasing an additional 874 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.